Covagen AG?is a clinical stage company that develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer.
Fynomers are small binding proteins that can be engineered to bind an antigen of interest. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Covagen is a privately held Swiss Biotech company with an internal lead bispecific anti-TNF/IL-17A FynomAb COVA322. In 2012, the company entered into a strategic alliance, which was recently expanded, with Mitsubishi Tanabe Pharma Corporation?for the development of bispecific FynomAbs.
Wagistrasse 25
CH-8952 Zurich-Schlieren
Switzerland.
Web: Covagen AG
